Language  ||  English : Spanish : Arabic  
Home Company Profile Business Opportunity QualityControl Manufacturing Contact Us
.
 
 
Products
  
  INJECTIONS
 
 
  ORALS
 
 
OLDER PACKAGING
 
 
 
npp 100 nandrolone
Click to enlarge
 

NPP 100

 
COMPOSITION
Each ml contains:
Nandrolone Phenylpropionate 100 mg
Oil Base q.s.
 
CHEMICAL INFORMATION
Chemical: 17β-hydroxy-19-nor-4-andro-
sten-3-one
Molecular Formula: C18H26O2
Molecular Weight: 274.3995 g/mol
 
 
COA
 
Chem Structure
DESCRIPTION
NPP 100 and NPP 150 are injectable anabolic preparations containing the short-acting nandrolone phenylpropionate ester. Serum nandrolone levels rapidly increase after IM administration with peak serum levels being reached within 24 to 36 hours. NPP clears rapidly avoiding the retention issues associated with the traditional nandrolone decanoate. Nandrolone phenylpropionate accelerates muscle growth, stimulates appetite, increases red blood cell production, and improves bone density.
INDICATIONS
Osteoporosis due to androgen deficiency in hypogonadal males.
Treatment of anemia in cases of renal insufficiency where oxymetholone is contraindicated.
Restoration of muscle mass in patients with muscular atrophy after traumatic recovery.
ADVERSE REACTIONS
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anti-coagulant therapy.
Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea.
CONTRAINDICATIONS
Not for use in women or children.
Patients with known hypersensitivity to any ingredients in this product.
Patients with known or suspected prostatic, testicular, hepatic, or mammary carcinoma.
Patients with nephrosis or the nephrotic phase of nephritis, hypercalcaemia, oedema, jaundice, or liver or kidney disease with impaired bilirubin excretion.
Products containing androgens should not be used in women as they may cause virilization and fetal harm.
Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine or a history of these conditions, since anabolic steroids may induce salt and fluid retention.
PRECAUTIONS
Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs
to patients with a history of myocardial infarction or coronary artery disease.
Patients on oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.
Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage of insulin and other hypoglycemic drugs.
DRUG INTERACTIONS
Oral hypoglycemic agents: may inhibit the metabolism of oral hypoglycemic agents which may require adjustment of dosage.
Anticoagulants: Patients on anticoagulants should be carefully monitored during anabolic steroid therapy as anabolic steroids may increase sensitivity to oral anticoagulants. Patients should be monitored regularly during anabolic steroid therapy, particularly during initiation and termination of therapy.
PATIENT MONITORING
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests - AST/ALT
Prostatic specific antigen - PSA, Testosterone: total, free, and bioavailable. Dihydrotestosterone & Estradiol
Male patients over 40 should undergo a digital rectal examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with difficulty in urination or with changes in voiding habits.
DOSAGE AND ADMINISTRATION
Adult male: 100 - 150mg injected IM every 3 - 5 days for a duration of 8 to 12 weeks.
PRESENTATION
NPP 100 (100mg/ml) in 10ml multiple dose vial OR 10 ampules of 1ml each.
NPP 150 (150mg/ml) in 10ml multiple dose vial OR 10 ampules of 1ml each.
STORAGE
Store in a cool dry place between 15 - 25oC. Protect from light.
 
 
  PRODUCT AUTHENTICATION : NEWS / EVENTS  
 
 
 
 
 
 
  Magnum Pharmaceuticals Authentication

Try our new method to quickly authenticate your product using the 2D barcode.
Click the respective link to download the QR Reader app for your phone.

Android OS | Blackberry OS | iOS | Windows Phone OS

 
 
 
TERMS & CONDITIONS   PAYMENT   SHIPPING
2012 © All Rights Reserved Magnum Pharmaceuticals Co., Ltd.

Please Note : We do not sell or ship to the USA, Europe, Australia or any other locations where prohibited. All information contained within this website or in any literature provided is not a prescription to use. Please seek the advice of a physician specializing in Andrology before use.
Not affiliated with Magnum Pharma (USA), Magnum Pharmaceuticals Inc. (USA), Magnum Chemi-Tech Ltd., or Magnum Nutraceuticals (Asia) Pte Ltd.

Distributors must submit licensing, a company profile, and our completed distributor application for approval prior to ordering.